The Pulse
UK regulator sets out next stage for London AI device sandbox
Selected AI medical device makers will be invited to submit full applications after their initial expressions of interest are screened. The MHRA says an invitation will not amount to acceptance or authorisation to deploy a device.

Selected AI medical device manufacturers will be invited to submit full applications after initial screening for a London NHS regulatory sandbox. The Medicines and Healthcare products Regulatory Agency (MHRA) set out the next stage of the process in an update on 18 November.
An invitation will not mean a manufacturer has been accepted onto the programme or authorised to deploy a device. Deployment will depend on an assessment against relevant regulatory, clinical, governance and operational requirements.
Devices in clinical settings
Announced in June 2026, London Region I will select up to 10 AI medical device manufacturers for its initial phase. They will work with NHS providers across London to deploy technologies in live clinical settings under MHRA oversight.
The programme is being run with NHS England (London) and the London Health Innovation Networks. The regulator says it aims to generate real-world evidence of ongoing safety and effectiveness to inform regulatory decisions and support a clearer route to wider adoption.
The regulator is particularly interested in devices supporting preventative and proactive care, especially heart health, and those that increase the capacity and capability of neighbourhood and community services. It is also interested in technology that expands digital access to healthcare, including through the NHS App, and other innovations that could improve patient outcomes and healthcare delivery in London.
Who can apply
Expressions of interest are welcome from AI-enabled medical device manufacturers and NHS provider organisations in Greater London. Organisations seeking to act as both manufacturer and provider can apply, as can provider-manufacturer partnerships wishing to participate together.
Manufacturers that have not yet submitted an expression of interest should do so by 31 December 2026, the MHRA says, citing the level of interest in the programme. The wider call will remain open until 10 devices have been successfully selected, assessed and deployed.
There is no application fee, but applicants are responsible for their own application costs. Separate manufacturer and provider forms are available; organisations applying in both roles, or partnerships applying together, should submit the forms for each role or organisation in a single email.
Information manufacturers should provide
Manufacturers should explain whether they already have a relationship with an eligible London NHS service provider willing and able to submit a pre-matched joint expression of interest. They should also identify any other regulatory body they are in contact with and describe the device's stage in the regulatory process, whether before market, under assessment or already on the market.
If a device is not yet certified, the regulator asks for a summary of the existing quality management system, including its maturity, documentation, scope and resources. The summary has a maximum length of 200 words.
Applicants should also say whether the device is deployed in another jurisdiction and, if so, attach or indicate evidence that can be checked, such as a certificate or a link to a public database.
After screening
Manufacturers invited to make a full application will provide further information about their proposed technology and provider partnership. Full applications will be progressed on a rolling basis, taking account of programme capacity and emerging priorities.
Sources
Related stories
- UK Accepts All 44 AI Healthcare Regulation Recommendations
- California proposes mandatory AI safety checks and shutdown powers
- California report proposes mandatory independent checks for frontier AI
- EFF proposes liability and security rules for AI testing
- Australia plans mandatory independent tests for frontier AI